Adjuvant chemotherapy for breast cancer--a current controversy

Hiromitsu Jinno, Tadashi Ikeda, Kouichi Kubouchi, Kiyoshi Fujiwara, Masaki Kitajima

Research output: Contribution to journalArticle

Abstract

EBCTCG meta-analysis revealed a significant reduction in mortality in patients receiving chemotherapy irrespective of nodal status and ER status. Compared with CMF, 5-year RFS and OS favored the anthracycline-containing regimens, 57% vs 54% (p = 0.006) and 72% vs 69% (p = 0.02), respectively. No survival benefit was obtained for CMF durations greater than 6 months. Delaying radiation therapy for several months after breast-conserving surgery until the completion of adjuvant chemotherapy appears safe and may be preferable for patients at high risk of distant metastasis. No difference in disease-free survival for the 3 dose levels of doxorubicin (60, 75, and 90 mg/m2) was found. Higher doses (100 mg/m2) of epirubicin led to a high survival rate in women with poor-prognosis disease. Dose-dense therapy seems promising but still needs further investigation. Incorporation of taxanes into adjuvant chemotherapy for early breast cancer is also controversial.

Original languageEnglish
Pages (from-to)176-180
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number2
Publication statusPublished - 2004 Feb

Fingerprint

Adjuvant Chemotherapy
Breast Neoplasms
Taxoids
Epirubicin
Segmental Mastectomy
Anthracyclines
Doxorubicin
Disease-Free Survival
Meta-Analysis
Radiotherapy
Survival Rate
Neoplasm Metastasis
Drug Therapy
Survival
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Jinno, H., Ikeda, T., Kubouchi, K., Fujiwara, K., & Kitajima, M. (2004). Adjuvant chemotherapy for breast cancer--a current controversy. Gan to kagaku ryoho. Cancer & chemotherapy, 31(2), 176-180.

Adjuvant chemotherapy for breast cancer--a current controversy. / Jinno, Hiromitsu; Ikeda, Tadashi; Kubouchi, Kouichi; Fujiwara, Kiyoshi; Kitajima, Masaki.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 31, No. 2, 02.2004, p. 176-180.

Research output: Contribution to journalArticle

Jinno, H, Ikeda, T, Kubouchi, K, Fujiwara, K & Kitajima, M 2004, 'Adjuvant chemotherapy for breast cancer--a current controversy', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 31, no. 2, pp. 176-180.
Jinno H, Ikeda T, Kubouchi K, Fujiwara K, Kitajima M. Adjuvant chemotherapy for breast cancer--a current controversy. Gan to kagaku ryoho. Cancer & chemotherapy. 2004 Feb;31(2):176-180.
Jinno, Hiromitsu ; Ikeda, Tadashi ; Kubouchi, Kouichi ; Fujiwara, Kiyoshi ; Kitajima, Masaki. / Adjuvant chemotherapy for breast cancer--a current controversy. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2004 ; Vol. 31, No. 2. pp. 176-180.
@article{0c6bca1290a84222a1ee308bf93380ba,
title = "Adjuvant chemotherapy for breast cancer--a current controversy",
abstract = "EBCTCG meta-analysis revealed a significant reduction in mortality in patients receiving chemotherapy irrespective of nodal status and ER status. Compared with CMF, 5-year RFS and OS favored the anthracycline-containing regimens, 57{\%} vs 54{\%} (p = 0.006) and 72{\%} vs 69{\%} (p = 0.02), respectively. No survival benefit was obtained for CMF durations greater than 6 months. Delaying radiation therapy for several months after breast-conserving surgery until the completion of adjuvant chemotherapy appears safe and may be preferable for patients at high risk of distant metastasis. No difference in disease-free survival for the 3 dose levels of doxorubicin (60, 75, and 90 mg/m2) was found. Higher doses (100 mg/m2) of epirubicin led to a high survival rate in women with poor-prognosis disease. Dose-dense therapy seems promising but still needs further investigation. Incorporation of taxanes into adjuvant chemotherapy for early breast cancer is also controversial.",
author = "Hiromitsu Jinno and Tadashi Ikeda and Kouichi Kubouchi and Kiyoshi Fujiwara and Masaki Kitajima",
year = "2004",
month = "2",
language = "English",
volume = "31",
pages = "176--180",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy for breast cancer--a current controversy

AU - Jinno, Hiromitsu

AU - Ikeda, Tadashi

AU - Kubouchi, Kouichi

AU - Fujiwara, Kiyoshi

AU - Kitajima, Masaki

PY - 2004/2

Y1 - 2004/2

N2 - EBCTCG meta-analysis revealed a significant reduction in mortality in patients receiving chemotherapy irrespective of nodal status and ER status. Compared with CMF, 5-year RFS and OS favored the anthracycline-containing regimens, 57% vs 54% (p = 0.006) and 72% vs 69% (p = 0.02), respectively. No survival benefit was obtained for CMF durations greater than 6 months. Delaying radiation therapy for several months after breast-conserving surgery until the completion of adjuvant chemotherapy appears safe and may be preferable for patients at high risk of distant metastasis. No difference in disease-free survival for the 3 dose levels of doxorubicin (60, 75, and 90 mg/m2) was found. Higher doses (100 mg/m2) of epirubicin led to a high survival rate in women with poor-prognosis disease. Dose-dense therapy seems promising but still needs further investigation. Incorporation of taxanes into adjuvant chemotherapy for early breast cancer is also controversial.

AB - EBCTCG meta-analysis revealed a significant reduction in mortality in patients receiving chemotherapy irrespective of nodal status and ER status. Compared with CMF, 5-year RFS and OS favored the anthracycline-containing regimens, 57% vs 54% (p = 0.006) and 72% vs 69% (p = 0.02), respectively. No survival benefit was obtained for CMF durations greater than 6 months. Delaying radiation therapy for several months after breast-conserving surgery until the completion of adjuvant chemotherapy appears safe and may be preferable for patients at high risk of distant metastasis. No difference in disease-free survival for the 3 dose levels of doxorubicin (60, 75, and 90 mg/m2) was found. Higher doses (100 mg/m2) of epirubicin led to a high survival rate in women with poor-prognosis disease. Dose-dense therapy seems promising but still needs further investigation. Incorporation of taxanes into adjuvant chemotherapy for early breast cancer is also controversial.

UR - http://www.scopus.com/inward/record.url?scp=1542288121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542288121&partnerID=8YFLogxK

M3 - Article

C2 - 14997747

AN - SCOPUS:1542288121

VL - 31

SP - 176

EP - 180

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 2

ER -